Gland Pharma Share Price
Sector: Biotechnology & Drugs
1783.50 -9.00 (-0.50%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
1780.15
Today’s High
1803.60
52 Week Low
1200
52 Week High
2220.95
1785.70 -6.60 (-0.37%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
1781.80
Today’s High
1801.80
52 Week Low
1277.80
52 Week High
2220.95
Key Metrics
- Market Cap (In Cr) 29491.85
- Beta 0.61
- Div. Yield (%) 1
- P/B 3.23
- TTM P/E 37.56
- Peg Ratio -2.51
- Sector P/E 22.67
- D/E 0
- Open Price 1785
- Prev Close 1792.5
Gland Pharma Analysis
Price Analysis
-
1 Week4.98%
-
3 Months11.68%
-
6 Month-1.76%
-
YTD0.73%
-
1 Year0.4%
Risk Meter
- 32% Low risk
- 32% Moderate risk
- 32% Balanced Risk
- 32% High risk
- 32% Extreme risk
Recos
- Strong Sell
- Sell
- Hold
- Buy
- Strong Buy
Analysts' Views
- Ratings
- Current
- 1 W Ago
- 1 M Ago
- 3 M Ago
- Strong Buy
- 4
- 4
- 4
- 4
- Buy
- 1
- 1
- 0.00
- 0.00
- Hold
- 1
- 1
- 1
- 1
- Sell
- 3
- 3
- 3
- 3
- Strong Sell
- 2
- 2
- 2
- 2
- Total
- 11
- 11
- 10
- 10
Gland Pharma News
Stocks to watch: Vedanta, BEL, Yes Bank, REC among shares in focus today
1 min read . 05 Jun 2025Stocks to buy for long term: Pankaj Pandey of ICICI Securities picks 5 names
4 min read . 27 May 2025Dixon Tech, NHPC to Hindalco: Six stocks that declared dividend with Q4 results
2 min read . 21 May 2025Gland Pharma Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2025
- Total Revenue
- 5616.5
- Selling/ General/ Admin Expenses Total
- 1600.72
- Depreciation/ Amortization
- 377.87
- Other Operating Expenses Total
- 656.48
- Total Operating Expense
- 4725.45
- Operating Income
- 891.05
- Net Income Before Taxes
- 1062.66
- Net Income
- 698.53
- Diluted Normalized EPS
- 42.4
- Period
- 2025
- Total Assets
- 11224.92
- Total Liabilities
- 2074.18
- Total Equity
- 9150.74
- Tangible Book Valueper Share Common Eq
- 533.93
- Period
- 2025
- Cashfrom Operating Activities
- 914.73
- Cashfrom Investing Activities
- 1704.74
- Cashfrom Financing Activities
- -433.48
- Net Changein Cash
- 2199.12
- Period
- 2024
- Total Revenue
- 5664.72
- Selling/ General/ Admin Expenses Total
- 2012.94
- Depreciation/ Amortization
- 344.57
- Other Operating Expenses Total
- 55.4
- Total Operating Expense
- 4676.22
- Operating Income
- 988.51
- Net Income Before Taxes
- 1132.54
- Net Income
- 772.46
- Diluted Normalized EPS
- 46.88
- Period
- 2024
- Total Assets
- 10661.25
- Total Liabilities
- 1937.4
- Total Equity
- 8723.84
- Tangible Book Valueper Share Common Eq
- 508.13
- Period
- 2024
- Cashfrom Operating Activities
- 996.8
- Cashfrom Investing Activities
- -1756.91
- Cashfrom Financing Activities
- -799.42
- Net Changein Cash
- -1551.81
- Period
- 2023
- Total Revenue
- 3624.6
- Selling/ General/ Admin Expenses Total
- 810
- Depreciation/ Amortization
- 146.74
- Other Operating Expenses Total
- 9.73
- Total Operating Expense
- 2802.95
- Operating Income
- 821.65
- Net Income Before Taxes
- 1054.58
- Net Income
- 781.04
- Diluted Normalized EPS
- 50.26
- Period
- 2023
- Total Assets
- 8777.54
- Total Liabilities
- 818.81
- Total Equity
- 7958.72
- Tangible Book Valueper Share Common Eq
- 482.51
- Period
- 2023
- Cashfrom Operating Activities
- 363.97
- Cashfrom Investing Activities
- 1208.19
- Cashfrom Financing Activities
- 14.92
- Net Changein Cash
- 1590.08
- Period
- 2022
- Total Revenue
- 4400.71
- Selling/ General/ Admin Expenses Total
- 694.61
- Depreciation/ Amortization
- 110.3
- Other Operating Expenses Total
- 3.79
- Total Operating Expense
- 3000.67
- Operating Income
- 1400.03
- Net Income Before Taxes
- 1618.55
- Net Income
- 1211.66
- Diluted Normalized EPS
- 73.65
- Period
- 2022
- Total Assets
- 7833.62
- Total Liabilities
- 676
- Total Equity
- 7157.62
- Tangible Book Valueper Share Common Eq
- 434.87
- Period
- 2022
- Cashfrom Operating Activities
- 790.77
- Cashfrom Investing Activities
- -1002.62
- Cashfrom Financing Activities
- 34.9
- Net Changein Cash
- -173.64
- Period
- 2021
- Total Revenue
- 3462.88
- Selling/ General/ Admin Expenses Total
- 590.16
- Depreciation/ Amortization
- 98.78
- Other Operating Expenses Total
- 0.12
- Total Operating Expense
- 2259.43
- Operating Income
- 1203.45
- Net Income Before Taxes
- 1334.81
- Net Income
- 996.96
- Diluted Normalized EPS
- 62.99
- Period
- 2021
- Total Assets
- 6496.08
- Total Liabilities
- 592.84
- Total Equity
- 5903.24
- Tangible Book Valueper Share Common Eq
- 360.85
- Period
- 2021
- Cashfrom Operating Activities
- 604.93
- Cashfrom Investing Activities
- -1524
- Cashfrom Financing Activities
- 1238.46
- Net Changein Cash
- 322.97
- Period
- 2020
- Total Revenue
- 2633.24
- Selling/ General/ Admin Expenses Total
- 514.31
- Depreciation/ Amortization
- 94.59
- Other Operating Expenses Total
- 4.31
- Total Operating Expense
- 1772.36
- Operating Income
- 860.88
- Net Income Before Taxes
- 992.87
- Net Income
- 772.86
- Diluted Normalized EPS
- 46.5
- Period
- 2020
- Total Assets
- 4086.04
- Total Liabilities
- 439.8
- Total Equity
- 3646.23
- Tangible Book Valueper Share Common Eq
- 223.31
- Period
- 2020
- Cashfrom Operating Activities
- 700.94
- Cashfrom Investing Activities
- -766.08
- Cashfrom Financing Activities
- -6.87
- Net Changein Cash
- -66.91
- Period
- 2019
- Total Revenue
- 2044.2
- Selling/ General/ Admin Expenses Total
- 432.64
- Depreciation/ Amortization
- 82.12
- Other Operating Expenses Total
- 1.05
- Total Operating Expense
- 1439.82
- Operating Income
- 604.38
- Net Income Before Taxes
- 686.28
- Net Income
- 451.86
- Diluted Normalized EPS
- 28.48
- Period
- 2019
- Total Assets
- 3523.55
- Total Liabilities
- 661.55
- Total Equity
- 2862
- Tangible Book Valueper Share Common Eq
- 175.28
- Period
- 2019
- Cashfrom Operating Activities
- 185.26
- Cashfrom Investing Activities
- -314.14
- Cashfrom Financing Activities
- -3.12
- Net Changein Cash
- -136.44
- Period
- 2025-03-31
- Total Revenue
- 1424.91
- Selling/ General/ Admin Expenses Total
- 425.97
- Depreciation/ Amortization
- 95.76
- Other Operating Expenses Total
- 163.47
- Total Operating Expense
- 1173.16
- Operating Income
- 251.75
- Net Income Before Taxes
- 288.33
- Net Income
- 186.54
- Diluted Normalized EPS
- 11.32
- Period
- 2025-03-31
- Total Assets
- 11224.92
- Total Liabilities
- 2074.18
- Total Equity
- 9150.74
- Tangible Book Valueper Share Common Eq
- 533.93
- Period
- 2025-03-31
- Cashfrom Operating Activities
- 914.73
- Cashfrom Investing Activities
- 1704.74
- Cashfrom Financing Activities
- -433.48
- Net Changein Cash
- 2199.12
- Period
- 2024-12-31
- Total Revenue
- 1384.05
- Selling/ General/ Admin Expenses Total
- 397.52
- Depreciation/ Amortization
- 96.33
- Other Operating Expenses Total
- 163.87
- Total Operating Expense
- 1120.42
- Operating Income
- 263.63
- Net Income Before Taxes
- 299.3
- Net Income
- 204.69
- Diluted Normalized EPS
- 12.42
- Period
- 2024-12-31
- Period
- 2024-12-31
- Period
- 2024-09-30
- Total Revenue
- 1405.83
- Selling/ General/ Admin Expenses Total
- 375.19
- Depreciation/ Amortization
- 93.83
- Other Operating Expenses Total
- 158.13
- Total Operating Expense
- 1202.6
- Operating Income
- 203.23
- Net Income Before Taxes
- 256.78
- Net Income
- 163.53
- Diluted Normalized EPS
- 9.93
- Period
- 2024-09-30
- Total Assets
- 10866.89
- Total Liabilities
- 2078.89
- Total Equity
- 8788
- Tangible Book Valueper Share Common Eq
- 511.24
- Period
- 2024-09-30
- Cashfrom Operating Activities
- 643.63
- Cashfrom Investing Activities
- 2212.64
- Cashfrom Financing Activities
- -402.74
- Net Changein Cash
- 2463.02
- Period
- 2024-06-30
- Total Revenue
- 1401.71
- Selling/ General/ Admin Expenses Total
- 402.04
- Depreciation/ Amortization
- 91.96
- Other Operating Expenses Total
- 171.01
- Total Operating Expense
- 1229.28
- Operating Income
- 172.44
- Net Income Before Taxes
- 218.24
- Net Income
- 143.76
- Diluted Normalized EPS
- 8.73
- Period
- 2024-06-30
- Period
- 2024-06-30
- Period
- 2024-03-31
- Total Revenue
- 1537.45
- Selling/ General/ Admin Expenses Total
- 409.49
- Depreciation/ Amortization
- 92.61
- Other Operating Expenses Total
- 169.93
- Total Operating Expense
- 1271.41
- Operating Income
- 266.04
- Net Income Before Taxes
- 298.23
- Net Income
- 192.42
- Diluted Normalized EPS
- 11.67
- Period
- 2024-03-31
- Total Assets
- 10661.25
- Total Liabilities
- 1937.4
- Total Equity
- 8723.84
- Tangible Book Valueper Share Common Eq
- 508.13
- Period
- 2024-03-31
- Cashfrom Operating Activities
- 996.8
- Cashfrom Investing Activities
- -1756.91
- Cashfrom Financing Activities
- -799.42
- Net Changein Cash
- -1551.81
- Period
- 2023-12-31
- Total Revenue
- 1545.16
- Selling/ General/ Admin Expenses Total
- 409.37
- Depreciation/ Amortization
- 105.34
- Other Operating Expenses Total
- 180.16
- Total Operating Expense
- 1294.11
- Operating Income
- 251.05
- Net Income Before Taxes
- 283.16
- Net Income
- 191.86
- Diluted Normalized EPS
- 11.65
- Period
- 2023-12-31
- Period
- 2023-12-31
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Gland Pharma Technical
Moving Average
SMA
- 5 Day1734.78
- 10 Day1722.72
- 20 Day1666.59
- 50 Day1539.87
- 100 Day1537.16
- 300 Day1650.49
Gland Pharma Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Ipca Laboratories
- 1356.2
- 11.8
- 0.88
- 1757.65
- 1060.95
- 34288.6
- Ajanta Pharma
- 2571.55
- 4.55
- 0.18
- 3485.75
- 2022.05
- 32160.35
- Gland Pharma
- 1783.5
- -9
- -0.5
- 2220.95
- 1200
- 29491.85
- J B Chemicals And Pharmaceutical
- 1772
- 20.25
- 1.16
- 2029
- 1303
- 27698.4
- Wockhardt
- 1653.55
- -2.3
- -0.14
- 1870
- 578.6
- 26912.13
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Ipca Laboratories
- 39.12
- 4.96
- 13.68
- 11.25
- Ajanta Pharma
- 35.14
- 8.52
- 22.49
- 19.6
- Gland Pharma
- 41.99
- 3.21
- 12.34
- 19.59
- J B Chemicals And Pharmaceutical
- 43.24
- 8.15
- 20.84
- 16.36
- Wockhardt
- -
- 6.4
- -9.24
- -11.98
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 20-May-25
- Audited Results & Final Dividend
- 03-Feb-25
- Quarterly Results
- 04-Nov-24
- Quarterly Results
- 06-Aug-24
- Quarterly Results
- 22-May-24
- Audited Results & Final Dividend
- 14-Feb-24
- Quarterly Results
- 06-Nov-23
- Quarterly Results
- 07-Aug-23
- Quarterly Results
- 18-May-23
- Audited Results & A.G.M.
- 23-Jan-23
- Quarterly Results
- Meeting Date
- Announced on
- Purpose
- 28-Aug-25
- 20-May-25
- AGM
- 01-Apr-25
- 28-Feb-25
- POM
- 11-Mar-25
- 07-Feb-25
- POM
- 10-Dec-24
- 08-Nov-24
- POM
- 30-Aug-24
- 22-May-24
- AGM
- 20-Nov-23
- 19-Oct-23
- POM
- 31-Aug-23
- 01-Aug-23
- AGM
- 08-Mar-23
- 06-Feb-23
- POM
- 30-Aug-22
- 19-May-22
- AGM
- 22-Apr-22
- 21-Mar-22
- POM
- Announced on
- Record Date
- Ex-Dividend
- Dividend Value
- 20-May-25
- 14-Aug-25
- -
- 18
- 22-May-24
- 16-Aug-24
- 16-Aug-24
- 20


